Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 / 2 Trials for Everolimus (DB01590)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03805399FUSCC Refractory TNBC Umbrella (FUTURE)Treatment